Pharmaceutical companies complain of unnecessary waste of money on products being sold without problems. Pharmaceutical companies are struggling ahead of the general drug price revaluation. There are many concerns that the biological equivalent test, which was conducted with the aim of maintaining drug prices, could lead to a reduction in drug prices due to delays in submitting data due to COVID-19. The pharmaceutical industry continues to ask health authorities to extend the deadline for submitting data, but it has not yet been carried out. According to the industry on the 25th, the HIRA recently held a briefing session on the revaluation of the upper limit of registered drugs and proposed a schedule to receive reval